Tracing Large Pharmaceutical Companies’ Choices
This content is for members
AbbVie Inc (ABBV)
New Breakthrough Immuno-Oncology Products
This content is for members
Prohost Letter #412 Part 3
This content is for members
Prohost Letter #407
This content is for members
CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY
This content is for members
Good News from Juno Therapeutics and from Abbvie. Disappointing News for Clovis Oncology
Juno Therapeutics (JUNO) is due to receive a fee payment of $50 million from Celgene. The reason for this compensation is that Celgene has exercised its …
Prohost Letter #392
This content is for members
Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?
The market looks like angry, probably very angry, as stocks are in a severe selloff mood. There will be many explanations like usual, but it is difficult for …
Gilead Collaborates with Galapagos on its Arthritis Drug. What’s Next for the Biotech Industry?
This content is for members
News That Makes A Difference. See ENTA. ARRY. and TSRO
This content is for members
URGENT BREAKING NEWS
The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with …
Portola Is on the Right Track
This content is for members
Halozyme: More Proof of Concept and Good Results on a Bad Cancer
This content is for members
From the EASL Meeting
This content is for members
Mergers and Acquisitions and Their Benefits. Receptos Refreshing Performance
This content is for members
Gilead: The Importance of Sovaldi Approval in Japan, A New MS Drug and More News.
This content is for members